PTPRC and breast carcinoma: Ultimately, this activated CD45+CD8+ effector T cells and incapacitated CD4+CD25+Foxp3+ Tregs, transforming “cold” into “hot” tumors and enhancing the anti‐tumor effect of chemotherapeutic agents in breast cancer in vivo.